Kazia Shares Drop 17% After Announcing ADS Offering With Warrants
KZIA has more than doubled off its 52-week low of $4.86 on elevated volume (5.1× avg).
Summary
Kazia Therapeutics disclosed a tranched registered public offering of ADSs and warrants, sending shares down 17% to $14.10 in premarket trading. The offering follows Thursday's 16% surge after the company reported 100% clinical benefit in six evaluable Stage IV TNBC patients treated with paxalisib. The deal includes pre-funded warrants and Series A/B warrants exercisable at more than double the IPO price, with expirations tied to paxalisib trial readouts expected in late 2027 and early 2028. Proceeds will fund paxalisib development and working capital. Leerink Partners and Guggenheim Securities are joint bookrunners. The offering size and pricing were not disclosed, but the dilution and warrant overhang are pressuring the stock after a strong run.
At the time of this announcement, KZIA was trading at $13.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $193.1M. The 52-week trading range was $4.86 to $17.40. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.